
Rabeeul I. Zuberi
Examiner (ID: 5151, Phone: (571)272-7189 , Office: P/3749 )
| Most Active Art Unit | 3749 |
| Art Unit(s) | 3749, 3762, 3743 |
| Total Applications | 319 |
| Issued Applications | 196 |
| Pending Applications | 1 |
| Abandoned Applications | 125 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18879120
[patent_doc_number] => 20240002489
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => METHODS AND AGENTS FOR THE TREATMENT OF OCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/160355
[patent_app_country] => US
[patent_app_date] => 2023-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20178
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18160355
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/160355 | Methods and agents for the treatment of ocular disease | Jan 26, 2023 | Issued |
Array
(
[id] => 18738024
[patent_doc_number] => 20230346932
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => ETAR ANTIBODY, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/155644
[patent_app_country] => US
[patent_app_date] => 2023-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30155
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18155644
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/155644 | ET | Jan 16, 2023 | Issued |
Array
(
[id] => 18770844
[patent_doc_number] => 20230365644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 18/154020
[patent_app_country] => US
[patent_app_date] => 2023-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45895
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154020
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/154020 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Jan 11, 2023 | Pending |
Array
(
[id] => 18511397
[patent_doc_number] => 20230227545
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => MATERIALS AND METHODS OF IL-1BETA BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/151305
[patent_app_country] => US
[patent_app_date] => 2023-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56232
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18151305
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/151305 | MATERIALS AND METHODS OF IL-1BETA BINDING PROTEINS | Jan 5, 2023 | Pending |
Array
(
[id] => 18484922
[patent_doc_number] => 20230212236
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => PROTEIN SECRETORY FACTOR WITH HIGH SECRETORY EFFICIENCY AND AN EXPRESSION VECTOR COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/147181
[patent_app_country] => US
[patent_app_date] => 2022-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10973
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18147181
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/147181 | PROTEIN SECRETORY FACTOR WITH HIGH SECRETORY EFFICIENCY AND AN EXPRESSION VECTOR COMPRISING THE SAME | Dec 27, 2022 | Abandoned |
Array
(
[id] => 18739590
[patent_doc_number] => 20230348547
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 18/087045
[patent_app_country] => US
[patent_app_date] => 2022-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 99155
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18087045
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/087045 | Modified bovine G-CSF polypeptides and their uses | Dec 21, 2022 | Issued |
Array
(
[id] => 19020193
[patent_doc_number] => 20240076364
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/068977
[patent_app_country] => US
[patent_app_date] => 2022-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26715
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18068977
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/068977 | CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES | Dec 19, 2022 | Abandoned |
Array
(
[id] => 18628223
[patent_doc_number] => 20230287075
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES
[patent_app_type] => utility
[patent_app_number] => 18/065504
[patent_app_country] => US
[patent_app_date] => 2022-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20115
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065504
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/065504 | DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES | Dec 12, 2022 | Abandoned |
Array
(
[id] => 20272031
[patent_doc_number] => 12441800
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-14
[patent_title] => Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/077137
[patent_app_country] => US
[patent_app_date] => 2022-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 66
[patent_no_of_words] => 40603
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18077137
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/077137 | Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof | Dec 6, 2022 | Issued |
Array
(
[id] => 18657742
[patent_doc_number] => 20230303696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/077139
[patent_app_country] => US
[patent_app_date] => 2022-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45623
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18077139
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/077139 | Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses Thereof | Dec 6, 2022 | Pending |
Array
(
[id] => 19931751
[patent_doc_number] => 12304948
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia
[patent_app_type] => utility
[patent_app_number] => 18/071057
[patent_app_country] => US
[patent_app_date] => 2022-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 4
[patent_no_of_words] => 4801
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18071057
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/071057 | Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia | Nov 28, 2022 | Issued |
Array
(
[id] => 18468861
[patent_doc_number] => 20230203144
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => COMBINATION OF TWO OR MORE ANTI-C5 ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/059677
[patent_app_country] => US
[patent_app_date] => 2022-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33510
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059677
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/059677 | COMBINATION OF TWO OR MORE ANTI-C5 ANTIBODIES AND METHODS OF USE | Nov 28, 2022 | Abandoned |
Array
(
[id] => 18537484
[patent_doc_number] => 20230242577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/990515
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24286
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990515
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990515 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | Nov 17, 2022 | Abandoned |
Array
(
[id] => 18709157
[patent_doc_number] => 20230331769
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/990460
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24053
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990460
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990460 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | Nov 17, 2022 | Abandoned |
Array
(
[id] => 18537481
[patent_doc_number] => 20230242574
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/990492
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24286
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990492
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990492 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | Nov 17, 2022 | Abandoned |
Array
(
[id] => 18552125
[patent_doc_number] => 20230250132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/990438
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24291
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990438
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990438 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | Nov 17, 2022 | Abandoned |
Array
(
[id] => 18537483
[patent_doc_number] => 20230242576
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/990507
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24307
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990507
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990507 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | Nov 17, 2022 | Abandoned |
Array
(
[id] => 18537482
[patent_doc_number] => 20230242575
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/990497
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990497
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990497 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | Nov 17, 2022 | Abandoned |
Array
(
[id] => 18537480
[patent_doc_number] => 20230242573
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/990478
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24300
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990478
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990478 | METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN | Nov 17, 2022 | Abandoned |
Array
(
[id] => 18451559
[patent_doc_number] => 20230192837
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/054284
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14140
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -55
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054284
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054284 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES | Nov 9, 2022 | Pending |